We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TTEC:NASDAQTTEC Holdings, Inc. Analysis

Data as of 2026-05-06 - not real-time

$2.98

Latest Price

8/10Risk

Risk Level: High

Executive Summary

TTEC trades at a forward PE of ~2.2, far below the industry average of ~37, and its price‑to‑sales ratio sits at just 0.07, suggesting a deep value proposition on paper. However, the company posts a negative profit margin (-9%) and a trailing EPS of -$3.99, with a debt‑to‑equity ratio soaring above 800%, highlighting significant balance‑sheet strain. Technically, the stock is above its 20‑day SMA (2.95) and 50‑day SMA (2.74) but remains under the 200‑day SMA (3.27), while the MACD histogram is negative and the RSI sits near a neutral 53, indicating limited short‑term momentum. Volatility is extreme at 85% over the past 30 days and beta approaches 1.9, pointing to heightened price swings relative to the market. The recent news cycle notes a scheduled earnings release, but no material catalyst has emerged to shift sentiment. Bottom line: the market is pricing in severe earnings distress, yet the valuation multiples hint at upside if the company can turn around earnings and deleverage.
Investors should weigh the attractive valuation against the high financial and operational risk. In the near term, a cautious hold stance is prudent, while a medium‑term buy could be justified if forward earnings materialize and debt reduction progresses. Long‑term exposure may be warranted for those comfortable with a high‑risk, value‑oriented play.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Neutral technical indicators with bearish MACD histogram
  • High volatility and beta increasing price sensitivity
  • Current price near support but limited upside in the next weeks

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE of ~2.2 and target price of $5 imply ~68% upside
  • Potential earnings turnaround reflected in positive forward EPS
  • Undervaluation relative to industry peers despite balance‑sheet challenges

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Strategic positioning in high‑growth CX and AI services
  • Long‑term upside if debt reduction and profitability improve
  • Value‑oriented price multiples offering margin of safety for patient investors

Key Metrics & Analysis

Financial Health

Revenue Growth0.40%
Profit Margin-9.01%
P/E Ratio2.2
ROE-97.15%
ROA3.77%
Debt/Equity887.25
P/B Ratio1.5
Op. Cash Flow$121.1M
Free Cash Flow$63.8M
Industry P/E37.2

Technical Analysis

TrendNeutral
RSI52.9
Support$2.21
Resistance$3.63
MA 20$2.95
MA 50$2.74
MA 200$3.27
MACDBearish
VolumeDecreasing
Fear & Greed Index90.48

Valuation

Target Price$5.00
Upside/Downside67.79%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.92
Volatility85.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.